某公司年度市場(chǎng)營(yíng)銷計(jì)劃概述(編輯修改稿)
2025-03-03 17:36 本頁(yè)面
【文章內(nèi)容簡(jiǎn)介】 uC rit e riaF av o r ab l e met a a n al y sis r esu l tR eal r e l ap s e ra t eDingke174。TerbinafineGxProductMei Fu174。ItraconazoleGxYi Qi Kang174。ItraconazoleGxBeiJia174。TerbinafineGxLamisil174。Sporanox174。Dingke174。TerbinafineGxProduct客戶分析：消費(fèi)意向 在不同目標(biāo)適應(yīng)癥中客戶用藥意向分析（全國(guó)） 61%34%16%43%23% 23%0%10%20%30%40%50%60%70%80%90%100%T i n e a P a d i s O n y c h o m y c o s i sT o p i c a l o n l y O r a l o n l y B o th66% 39% Source: Lamisil Brand Positioning New Opportunity Exploration Study。 June 2023 by TNS 客戶分析：消費(fèi)意向的區(qū)域性差異 在不同目標(biāo)適應(yīng)癥中客戶用藥意向分析（區(qū)域） Source: Lamisil Brand Positioning New Opportunity Exploration Study。 June 2023 by TNS 2 9 . 34 9 . 21 8 . 82 9 . 84 4 . 24 6 . 63 5 . 35 7 . 54 2 . 63 1 . 22 4 . 01 5 . 52 3 . 62 7 . 72 4 . 70%20%40%60%80%100%B J N = 3 0 S H N = 3 0 G Z N = 3 0 W H N = 2 0 H Z N = 3 0T o p i ca l t r e a t m e n t o n l y O r a l t r e a t m e n t o n l y T o p i ca l o r a l t r e a t m e n t6 6 . 87 0 . 84 2 . 57 7 . 55 5 . 11 0 . 31 3 . 22 3 . 21 1 . 71 8 . 82 2 . 91 6 . 03 4 . 31 0 . 92 6 . 10%20%40%60%80%100%B J N = 3 0 S H N = 3 0 G Z N = 3 0 W H N = 2 0 H Z N = 3 0T o p i ca l t r e a t m e n t o n ly O r a l t r e a t m e n t o n ly T o p i ca l o r a l t r e a t m e n tOnychomycosis Tinea Pedis 患者就醫(yī)行為與疾病診療流程 Source:Chinese Statistics Yearbook 2023 LamisilO Study by TNS Company in 2023. LamisilO Study by Synovate pany in 2023. Based on Lamisil Sporanoxl IMS sales 2023Q4MAT. Unit: Million 發(fā)病率和患者池規(guī)模 就診率 治療方案選擇 品類與品牌選擇 依從性 Urban Population 594 Target Population 472 TP42% 198 OM6% 28 % 32 Other84% 166 Hosp15% Other85% 24 Diagnosed 27(85%) NonDiagnosed Diagnosed (83%) NonDiagnosed New Patient 16(61%) Repeat Patient 11(39%) New Patient (69%) Repeat Patient (31%) Oral Only (16%) Topical Only (61%) Topical Only (34%) Oral+Topical (23%) Oral+Topical (23%) Oral Only (43%) Oral Only 1week Topical Only 2~6week Oral+Topical 1week Oral Only 6~12weeks Topical Only 36~48week Oral+Topical 6~12week Patient share Market Value MS% Treatment Period Sporanox (TP48%。OM46%) 88m 41% 5~9 weeks L
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1